journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://www.readbyqxmd.com/read/29731187/corrigendum-to-inhibition-of-protein-phosphatase-5-suppresses-non-small-cell-lung-cancer-through-amp-activated-kinase-activation-lung-cancer-112-october-2017-81-89
#1
Feng-Shu Hsieh, Man-Hsin Hung, Cheng-Yi Wang, Yen-Lin Chen, Yung-Jen Hsiao, Ming-Hsien Tsai, Jia-Rong Li, Li-Ju Chen, Chih-Ting Shih, Tzu-I Chao, Kuen-Feng Chen
No abstract text is available yet for this article.
May 3, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29724454/the-eighth-tnm-classification-for-lung-cancer-what-is-next
#2
EDITORIAL
Ming-Sound Tsao, Ju-Yoon Yoon
No abstract text is available yet for this article.
April 25, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29773459/lung-adenocarcinoma-patient-with-egfr-19-exon-insert-mutation-and-its-response-to-icotinib
#3
LETTER
You-Cai Zhu, Kai-Qi Du, Wen-Xian Wang, Zheng-Bo Song, Chun-Wei Xu, Gang Chen, Wu Zhuang, Tang-Feng Lv, Yong Song
No abstract text is available yet for this article.
April 24, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29681404/excellent-treatment-response-with-pembrolizumab-in-a-lung-cancer-patient-who-developed-immune-mediated-acute-motor-sensory-axonal-polyneuropathy
#4
LETTER
Chih-Chieh Yen, Hui-Chen Su, Chang-Yao Chu, Shi-Jie Lai, Jing-Jou Yan, Wen-Pin Su, Wu-Chou Su
No abstract text is available yet for this article.
April 17, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29739705/building-the-case-for-comprehensive-hospital-based-tobacco-addiction-services-applying-the-ottawa-model-to-the-city-of-manchester
#5
LETTER
Matthew Evison, Sanjay Agrawal, Matthew Conroy, Neil Bendel, Navin Sewak, Andrew Fitzgibbon, Lorna McWilliams, Julie Jerram, David Regan, David Shackley, Richard Preece, Louise Brown, Phil Barber
No abstract text is available yet for this article.
April 13, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29567377/corrigendum-to-inhibition-of-protein-phosphatase-5-suppresses-non-small-cell-lung-cancer-through-amp-activated-kinase-activation-lung-cancer-112-october-2017-81-89
#6
Feng-Shu Hsieh, Man-Hsin Hung, Cheng-Yi Wang, Yen-Lin Chen, Yung-Jen Hsiao, Ming-Hsien Tsai, Jia-Rong Li, Li-Ju Chen, Chih-Ting Shih, Tzu-I Chao, Kuen-Feng Chen
No abstract text is available yet for this article.
March 19, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29573824/heterogeneous-met-gene-copy-number-and-egfr-mutation-elicit-discordant-responses-to-crizotinib-between-primary-and-metastatic-lesions-in-erlotinib-resistant-lung-adenocarcinoma
#7
LETTER
Katsuhiro Yoshimura, Masato Karayama, Yusuke Inoue, Tomoaki Kahyo, Naoki Inui, Masato Maekawa, Haruhiko Sugimura, Takafumi Suda
No abstract text is available yet for this article.
March 17, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748024/expression-of-brain-derived-neurotrophic-factor-and-its-receptor-trkb-is-associated-with-poor-prognosis-and-a-malignant-phenotype-in-small-cell-lung-cancer
#8
Shinichi Kimura, Taishi Harada, Kayo Ijichi, Kentaro Tanaka, Renpeng Liu, Daisuke Shibahara, Yuko Kawano, Kohei Otsubo, Yasuto Yoneshima, Eiji Iwama, Yoichi Nakanishi, Isamu Okamoto
OBJECTIVES: TrkB is a receptor for brain-derived neurotrophic factor (BDNF) and is highly expressed in various cancers, with BDNF-TrkB signaling having been implicated in tumor progression and metastasis. The role of the BDNF-TrkB system in small cell lung cancer (SCLC), a neuroendocrine cancer, has remained unclear, however. We examined BDNF and TrkB expression in SCLC patients as well as the function of BDNF-TrkB signaling in SCLC cell lines. MATERIALS AND METHODS: BDNF and TrkB expression in tumor specimens of 58 SCLC patients and 20 non-small cell lung cancer (NSCLC) patients was examined by immunohistochemistry and was scored on the basis of the distribution and intensity of staining...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748023/cost-effectiveness-analysis-of-policy-options-on-first-line-treatments-for-advanced-non-small-cell-lung-cancer-in-thailand
#9
Chulaporn Limwattananon, Supon Limwattananon, Onanong Waleekhachonloet, Thananan Rattanachotphanit
OBJECTIVES: Tyrosine kinase inhibitors (TKIs) have shown to be better for progression-free survival than chemotherapy as the first-line treatment for advanced, non-small cell lung cancer (NSCLC), especially in patients with epidermal growth factor receptor mutation (EGFR M+). This study evaluates under the Thai health system context, cost-effectiveness of (A) the use of platinum doublets for all without EGFR testing, and (B) an EGFR test followed by TKIs or platinum doublets conditional on test results...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748022/radiosurgery-alone-is-associated-with-favorable-outcomes-for-brain-metastases-from-small-cell-lung-cancer
#10
Tyler P Robin, Bernard L Jones, Arya Amini, Matthew Koshy, Laurie E Gaspar, Arthur K Liu, Sameer K Nath, Brian D Kavanagh, D Ross Camidge, Chad G Rusthoven
INTRODUCTION: Whole-brain radiation therapy (WBRT) is the standard approach for brain metastases (BM) arising in patients with small-cell lung cancer (SCLC), but the neurocognitive toxicities of WBRT are well documented. For this reason, stereotactic radiosurgery (SRS) alone is the preferred modality for limited BM in most histologies, but in SCLC there are few data exploring this approach. METHODS: We queried the National Cancer Database (NCDB) for patients with SCLC with BM at diagnosis and stratified by upfront SRS compared with upfront WBRT ± SRS...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748021/egfr-tkis-plus-chemotherapy-demonstrated-superior-efficacy-than-egfr-tkis-alone-as-first-line-setting-in-advanced-nsclc-patients-with-egfr-mutation-and-bim-deletion-polymorphism
#11
Sangtian Liu, Yayi He, Tao Jiang, Shengxiang Ren, Fei Zhou, Chao Zhao, Xuefei Li, Jie Zhang, Chunxia Su, Xiaoxia Chen, Weijing Cai, Guanghui Gao, Wei Li, Fengying Wu, Jiayu Li, Jing Zhao, Qiong Hu, Mingchuan Zhao, Caicun Zhou, Fred R Hirsch
BACKGROUND: Non-small-cell lung cancer (NSCLC) patients with both epidermal growth factor receptor (EGFR) positive mutation and B-cell chronic lymphocytic leukemia/lymphoma-like 11 (BIM) deletion polymorphism had a poor clinical response to EGFR-tyrosine kinase inhibitors (TKIs). The current study aimed to investigate the clinical efficacy and tolerability of EGFR-TKIs plus chemotherapy versus EGFR-TKIs alone as first-line treatment in advanced NSCLC patients with EGFR mutations and BIM deletion polymorphism...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748020/validation-of-the-8th-tnm-classification-for-small-cell-lung-cancer-in-a-retrospective-material-from-sweden
#12
Salomon Tendler, Vitali Grozman, Rolf Lewensohn, Georgios Tsakonas, Kristina Viktorsson, Luigi De Petris
BACKGROUND: The purpose of this study was to evaluate on a Swedish cohort of small cell lung cancer (SCLC) patients whether the 8th TNM staging system can provide additional prognostic information in comparison with the previous 6th and 7th TNM versions and the older 2-stage LD vs ED system. METHODS: We reviewed the medical records of patients (pts) with SCLC diagnosed between January 2008 and February 2016 in the Stockholm and Gotland region. Each patient file was revised and reclassified from the VASGL system to the 6th , 7th and 8th TNM system respectively...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748019/long-term-survival-with-erlotinib-in-advanced-lung-adenocarcinoma-harboring-synchronous-egfr-g719s-and-kras-g12c-mutations
#13
Biagio Ricciuti, Sara Baglivo, Vienna Ludovini, Angelo Sidoni, Giulio Metro, Marta Brambilla, Annamaria Siggillino, Maria Sole Reda, Alberto Rebonato, Daniele Maiettini, Rita Chiari
Although epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) mutations were thought to be mutually exclusive in patients with non-small cell lung cancer (NSCLC), the development of high sensitive large-scale mutation analysis, has increasingly shown that activating EGFR mutations occasionally coexist with other dominant genetic alterations. Herein, we discuss the case of a patient with advanced NSCLC harboring both the uncommon EGFR G719S and the KRAS G12C mutations, who was treated for 9 years with erlotinib achieving a long-term survival...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748018/facility-volume-and-postoperative-outcomes-for-malignant-pleural-mesothelioma-a-national-cancer-data-base-analysis
#14
Vivek Verma, Christopher A Ahern, Christopher G Berlind, William D Lindsay, Surbhi Grover, Melissa J Culligan, Joseph S Friedberg, Charles B Simone
PURPOSE: This study of a large, contemporary national database evaluated postoperative outcomes and overall survival (OS) for malignant pleural mesothelioma (MPM) by facility volume. METHODS: The National Cancer Database was queried for newly-diagnosed non-metastatic MPM undergoing definitive surgery (extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D)). Patients were dichotomized into those receiving therapy at a high-volume facility (HVF), defined a priori at the 90th percentile of case volume, with all others categorized as lower-volume facilities (LVFs)...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748017/antiangiogenic-therapy-for-patients-with-aggressive-or-refractory-advanced-non-small-cell-lung-cancer-in-the-second-line-setting
#15
REVIEW
Martin Reck, Marina Chiara Garassino, Martina Imbimbo, Frances A Shepherd, Mark A Socinski, Jin-Yuan Shih, Anne Tsao, Pablo Lee, Katherine B Winfree, Andreas Sashegyi, Rebecca Cheng, Rocio Varea, Benjamin Levy, Edward Garon
A majority of patients with advanced or metastatic non-small cell lung cancer (NSCLC) will experience disease progression after first-line therapy. Patients who have advanced NSCLC that is especially aggressive, which is defined as disease that rapidly progresses on first-line treatment or disease that is refractory to first-line treatment, have a critical unmet medical need. These patients have a poor prognosis in the second-line setting. Several studies have recently shown that treatment with an antiangiogenic therapy may benefit these patients...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748016/lorlatinib-induced-pulmonary-arterial-hypertension
#16
Alexandre Chabrol, Marie Mayenga, Abdul Momen Hamid, Sylvie Friard, Hélène Salvator, Hélèe Doubre, Séverine Fraboulet, Anne-Cécile Metivier, Emilie Catherinot, Elisabeth Rivaud, Marie Camille Chaumais, David Montani, Louis Jean Couderc, Colas Tcherakian
We report here the first cases, to our knowledge, of pulmonary arterial hypertension induced by lorlatinib. It s the first time that a tyrosine kinase inhibitor for lung cancer is associated with pulmonary arteriel hypertension.
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748015/association-between-radiation-heart-dosimetric-parameters-myocardial-infarct-and-overall-survival-in-stage-3-non-small-cell-lung-cancer-treated-with-definitive-thoracic-radiotherapy
#17
Chia Ching Lee, Huili Zheng, Yu Yang Soon, Ling Li Foo, Wee Yao Koh, Cheng Nang Leong, Balamurugan Vellayappan, Jeremy Chee Seong Tey, Ivan Weng Keong Tham
OBJECTIVES: The aim of this retrospective observational study is to assess the association between various radiation heart dosimetric parameters (RHDPs) and acute myocardial infarct (AMI) and overall survival (OS) outcomes in stage III non-small cell lung cancer (NSCLC) treated with definitive radiotherapy with or without chemotherapy. MATERIALS AND METHODS: We identified eligible patients treated at two institutions from 2007 to 2014. We linked their electronic medical records to the national AMI and death registries...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748014/the-combination-of-the-blood-based-tumor-biomarkers-cytokeratin-19-fragments-cyfra-21-1-and-carcinoembryonic-antigen-cea-as-a-potential-predictor-of-benefit-from-adjuvant-chemotherapy-in-early-stage-squamous-cell-carcinoma-of-the-lung-scc
#18
Thomas Muley, Vinzent Rolny, Ying He, Birgit Wehnl, Achim Escherich, Arne Warth, Christa Stolp, Marc A Schneider, Hendrik Dienemann, Michael Meister, Felix J Herth, Farshid Dayyani
OBJECTIVES: To determine whether the tumor biomarkers cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA), which are prognostic in early-stage non-small cell lung cancer (NSCLC), can predict which patients benefit from adjuvant chemotherapy (CTx). MATERIALS AND METHODS: Serum samples were collected preoperatively from patients with NSCLC who underwent resection. Samples were retrospectively analyzed for CYFRA 21-1 and CEA via electrochemiluminescence immunoassay...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748013/loss-of-c-ebp-%C3%AE-lip-drives-cisplatin-resistance-in-malignant-pleural-mesothelioma
#19
Joanna Kopecka, Iris C Salaroglio, Luisella Righi, Roberta Libener, Sara Orecchia, Federica Grosso, Vladan Milosevic, Preeta Ananthanarayanan, Luisa Ricci, Enrica Capelletto, Monica Pradotto, Francesca Napoli, Massimo Di Maio, Silvia Novello, Menachem Rubinstein, Giorgio V Scagliotti, Chiara Riganti
OBJECTIVES: Cisplatin-based chemotherapy is moderately active in malignant pleural mesothelioma (MPM) due to intrinsic drug resistance and to low immunogenicity of MPM cells. CAAT/enhancer binding protein (C/EBP)-β LIP is a pro-apoptotic and chemosensitizing transcription factor activated in response to endoplasmic reticulum (ER) stress. MATERIALS AND METHODS: We investigated if LIP levels can predict the clinical response to cisplatin and survival of MPM patients receiving cisplatin-based chemotherapy...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748012/a-phase-i-study-of-nintedanib-combined-with-cisplatin-gemcitabine-as-first-line-therapy-for-advanced-squamous-non-small-cell-lung-cancer-lume-lung-3
#20
Martin Forster, Allan Hackshaw, Tommaso De Pas, Manuel Cobo, Pilar Garrido, Yvonne Summers, Anne-Marie C Dingemans, Michael Flynn, David Schnell, Ute von Wangenheim, Arsene-Bienvenu Loembé, Rolf Kaiser, Siow Ming Lee
BACKGROUND: There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line treatment for advanced sqNSCLC patients, were evaluated. MATERIALS AND METHODS: A phase I, dose-escalation study administering drugs in a 21-day cycle: cisplatin (75 mg/m2 , Day 1), gemcitabine (1250 mg/m2 , Days 1 and 8) and nintedanib (Days 2-7, 9-21) were given for 4-6 cycles, followed by monotherapy until disease progression or adverse events (AEs)...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"